Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Express Scripts
Cipla
Covington
Johnson and Johnson
QuintilesIMS
Dow
Baxter
Julphar
Cerilliant

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below. ##STR00001##
Inventor(s): Kesicki; Edward A. (Seattle, WA), Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Puri; Kamal Deep (Lynnwood, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA)
Assignee: Icos Corporation (Indianapolis, IN)
Filing Date:Feb 12, 2013
Application Number:13/765,610
Claims:1. A method comprising inhibiting phosphatidylinositol 3-kinase activity in a cell with a compound ##STR00186## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the compound is ##STR00187##

4. The method of claim 1, further comprising administering the compound or a pharmaceutically acceptable salt thereof to an individual in need thereof.

5. The method of claim 4, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

6. The method of claim 4, wherein the compound is the S-enantiomer.

7. A method of inhibiting phosphatidylinositol 3-kinase delta activity in a cell, comprising administering to an individual in need thereof the compound ##STR00188## or a pharmaceutically acceptable salt thereof.

8. The method of claim 7, wherein the compound is ##STR00189##

9. The method of claim 7, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

10. The method of claim 7, wherein the compound is the S-enantiomer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Covington
Argus Health
Dow
US Department of Justice
Federal Trade Commission
Harvard Business School
McKinsey
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot